Iterum Therapeutics Focused On First Oral Penem

Emerging Company Profile: Iterum Therapeutics is developing a Phase III-ready penem antibiotic, sulopenem, which could be the first in its class to be administered orally. It’s the second foray into setting up an anti-infectives-focused company by a team of experienced biotech executives and entrepreneurs that previously took Durata’s dalbavancin through clinical development.